KPV
Overview
A C-terminal tripeptide fragment (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (alpha-MSH) that retains potent anti-inflammatory activity without melanogenic effects. KPV inhibits NF-kB nuclear translocation and reduces production of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6. It penetrates cell membranes and directly interacts with inflammatory signaling cascades, making it effective topically and orally for mucosal inflammation.
Key Research Findings
Preclinical studies demonstrated significant anti-inflammatory effects in colitis models, reducing mucosal inflammation and promoting epithelial barrier repair. Oral KPV-loaded nanoparticles showed targeted anti-inflammatory activity in the colon (Dalmasso et al., PLoS One, 2008). Investigated for inflammatory bowel disease, atopic dermatitis, and wound healing. Preclinical stage with limited human clinical data.
Oral, Topical, Subcutaneous injection
Research Phase
Interested in KPV?
Find a verified provider experienced with KPV protocols in your area. All providers are credentialed and use compliant sourcing.
Find a KPV ProviderRelated Peptides
Thymalin
InvestigationalA peptide bioregulator originally extracted from bovine thymus gland, consisting of a mixture of polypeptides that modulate immune function. Thymalin restores T-cell mediated immunity by promoting T-lymphocyte maturation and differentiation in the thymus. It also normalizes the ratio of T-helper to T-suppressor cells and enhances phagocytic activity of neutrophils and macrophages.
LL-37
Research PhaseThe only human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide cleaved from the precursor protein hCAP18. LL-37 disrupts microbial membranes through electrostatic interactions and exerts broad-spectrum activity against bacteria, fungi, and enveloped viruses. Beyond direct antimicrobial effects, it modulates innate immunity by recruiting immune cells, promoting angiogenesis, and regulating inflammatory cytokine release.
VIP (Vasoactive Intestinal Peptide)
InvestigationalA 28-amino acid neuropeptide widely distributed in the central and peripheral nervous systems and immune cells. VIP acts through VPAC1 and VPAC2 receptors to produce potent anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-12) and promoting regulatory T-cell differentiation. It also functions as a vasodilator, bronchodilator, and neuromodulator.
Thymosin Alpha 1 (Zadaxin)
InvestigationalA 28-amino acid peptide originally isolated from thymic tissue (thymosin fraction 5) that serves as a potent immunomodulator. Thymosin alpha 1 enhances T-cell maturation, dendritic cell function, and antibody responses by activating Toll-like receptors (TLR2, TLR9) on innate immune cells. It promotes Th1 immune responses and augments vaccine efficacy while modulating inflammatory cytokine production.